The University of Georgia has renewed its partnership with Lokahi Therapeutics, extending a program that engages students in identifying and evaluating underdeveloped therapeutic assets. The collaboration, centered in Lokahi’s ai² Futures Lab, leverages university resources to support the biotech firm’s pipeline development strategy.
The program, which operates under Lokahi Therapeutics—a subsidiary of Glucotrack Inc. (NASDAQ: GCTK)—involved 64 University of Georgia students in its inaugural year. Their work resulted in the identification of more than 45 potential acquisition targets, several of which advanced into formal pipeline discussions. Students focused on therapeutic asset evaluation, generating business recommendations that Lokahi reviews for potential licensing, partnerships, or acquisition.
Brian Peters, Senior Vice President of Lokahi’s ai² Division, highlighted the program’s role in providing a "scalable, capital-efficient process" for uncovering overlooked or deprioritized assets. The ai² platform integrates scientific, commercial, regulatory, and clinical expertise with emerging technologies to assess opportunities.
Andrew H. Potter, Director of the University of Georgia’s Office of University Experiential Learning, emphasized the educational value of the partnership. "Our continued participation reflects the strength of the experience and the value it creates for students seeking to understand how business strategy and healthcare innovation intersect," he stated.
The University of Georgia is part of a broader network of academic institutions collaborating with Lokahi’s ai² Futures Lab. The program aligns with Lokahi’s broader ai² initiative, which aims to bridge gaps in therapeutic development through structured evaluation processes.
